CA2705716C - Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies - Google Patents

Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies Download PDF

Info

Publication number
CA2705716C
CA2705716C CA2705716A CA2705716A CA2705716C CA 2705716 C CA2705716 C CA 2705716C CA 2705716 A CA2705716 A CA 2705716A CA 2705716 A CA2705716 A CA 2705716A CA 2705716 C CA2705716 C CA 2705716C
Authority
CA
Canada
Prior art keywords
rubella
antigen
cys
disulfide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2705716A
Other languages
English (en)
French (fr)
Other versions
CA2705716A1 (en
Inventor
Christian Scholz
Ralf Bollhagen
Alfred Engel
Elke Faatz
Peter Schaarschmidt
Barbara Upmeier
Toralf Zarnt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2705716A1 publication Critical patent/CA2705716A1/en
Application granted granted Critical
Publication of CA2705716C publication Critical patent/CA2705716C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/19—Rubella virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2705716A 2007-12-13 2008-12-11 Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies Active CA2705716C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07024190.6 2007-12-13
EP07024190 2007-12-13
PCT/EP2008/010532 WO2009074318A2 (en) 2007-12-13 2008-12-11 Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies

Publications (2)

Publication Number Publication Date
CA2705716A1 CA2705716A1 (en) 2009-06-18
CA2705716C true CA2705716C (en) 2013-03-19

Family

ID=40671057

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2705716A Active CA2705716C (en) 2007-12-13 2008-12-11 Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies

Country Status (7)

Country Link
US (1) US8551696B2 (enExample)
EP (1) EP2222694B1 (enExample)
JP (1) JP5461423B2 (enExample)
CN (1) CN101939330B (enExample)
CA (1) CA2705716C (enExample)
ES (1) ES2450998T3 (enExample)
WO (1) WO2009074318A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2706115A1 (en) * 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays
CN104755499B (zh) * 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白
JP6695812B2 (ja) * 2014-05-14 2020-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピン及びｈｅｒ２のドメインｉｉに結合するｈｅｒ３／ｈｅｒ２二重特異性抗体
WO2017055235A1 (en) * 2015-09-30 2017-04-06 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
KR102943992B1 (ko) * 2015-12-15 2026-03-25 에프. 호프만-라 로슈 아게 트랜스글루타미나제 인식 부위를 갖는 fkbp 도메인
US12436148B2 (en) * 2018-07-02 2025-10-07 Siemens Healthcare Diagnostics Inc. Direct immunoassay measurement of autoantibodies
DE102019004812B4 (de) 2019-07-10 2021-03-18 Institut Virion-Serion GmbH Würzburg Rubella Virus Spike Konstrukt
CN115197941A (zh) * 2021-04-08 2022-10-18 中国科学院分子细胞科学卓越创新中心 具有分子伴侣功能的rna及其应用
CN116333164B (zh) * 2022-12-08 2026-07-21 青岛硕景生物科技有限公司 一种风疹病毒特异性融合蛋白抗原、其制备方法及检测试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501093A (ja) 1996-09-26 2001-01-30 メディカル リサーチ カウンシル シャペロン断片
ES2378272T3 (es) * 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
ATE522603T1 (de) 2001-06-22 2011-09-15 Hoffmann La Roche Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
US7604935B2 (en) * 2005-10-26 2009-10-20 Roche Diagnostics Operations, Inc. Soluble rubella E1 envelope protein variants
EP1780282B1 (en) * 2005-10-26 2010-12-08 Roche Diagnostics GmbH Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies

Also Published As

Publication number Publication date
ES2450998T3 (es) 2014-03-26
CN101939330B (zh) 2014-06-04
EP2222694B1 (en) 2014-01-15
US20110059552A1 (en) 2011-03-10
US8551696B2 (en) 2013-10-08
WO2009074318A2 (en) 2009-06-18
HK1148026A1 (en) 2011-08-26
CN101939330A (zh) 2011-01-05
WO2009074318A3 (en) 2009-07-30
EP2222694A2 (en) 2010-09-01
JP5461423B2 (ja) 2014-04-02
JP2011505811A (ja) 2011-03-03
CA2705716A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
US8551696B2 (en) Rubella E1 envelope protein variants and their use in detection of anti-rubella antibodies
CA2667177C (en) Slpa as a tool for recombinant protein and enzyme technology
CA2856187C (en) Soluble immunoreactive treponema pallidum tpn47 antigens
US11567079B2 (en) Soluble and immunoreactive variants of HTLV capsid antigen P24
EP1780282B1 (en) Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies
US7604935B2 (en) Soluble rubella E1 envelope protein variants
JP7818525B2 (ja) 抗体－免疫アッセイでの使用のためのコロナヌクレオカプシド抗原
CA3136756C (en) SPICULE STRUCTURE OF RUBELLA VIRUS
HK1148026B (en) Novel rubella e1 envelope protein variants and their use in the detection of antirubella antibodies

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124